NAPLEX
Practice Test 4 for NAPLEX: real questions and explanations from the Varsity Tutors practice-test pool.
0%
0 / 25 answered
Question 1 of 25
A 67-year-old man (82 kg) receives a new prescription for dabigatran capsules. He says he plans to place a month’s supply into a pill organizer to improve adherence. What corrective action should the pharmacist recommend?
Question Navigator
A 67-year-old man (82 kg) receives a new prescription for dabigatran capsules. He says he plans to place a month’s supply into a pill organizer to improve adherence. What corrective action should the pharmacist recommend?
Explanation: This question tests moisture protection for dabigatran capsules, crucial for anticoagulation stability. The key factor is humidity sensitivity, as exposure can degrade the drug, affecting bioavailability. Choice A is the best because original packaging shields from moisture, ensuring consistent dosing and preventing clotting risks. Choice B is incorrect as pill organizers expose to air, while choice C alters formulation unsafely. Choice D risks freezing damage. Clinically, advise against repackaging moisture-sensitive drugs to maintain efficacy. For adherence aids, suggest alternatives like reminders over organizers for such medications.
A 66-year-old woman (74 kg) takes apixaban 5 mg twice daily for venous thromboembolism and asks for an OTC product for new-onset low back pain after gardening. Medical history: hypertension; allergies: none. Current OTC/supplements include naproxen 220 mg twice daily started yesterday and glucosamine/chondroitin. Which action should the pharmacist take regarding this OTC product?
Explanation: This question tests OTC NSAID use with anticoagulants. The key patient-specific factor is apixaban increasing bleeding risk with NSAIDs like naproxen. Recommending switch to acetaminophen or topical diclofenac is best because they offer analgesia with lower systemic bleeding risks. Continuing with aspirin (A) or naproxen (C) heightens hemorrhage; stopping apixaban (D) risks thrombosis. A clinical pearl is using HAS-BLED for assessment. Guidelines advise avoiding oral NSAIDs with DOACs, preferring alternatives.
A 37-year-old woman (weight 59 kg) is prescribed enoxaparin for 7 days after an ankle fracture and asks about the prefilled syringe air bubble. Medical history: none. Current medications: enoxaparin 40 mg subcutaneously once daily for 7 days, naproxen 500 mg orally twice daily as needed. Allergies: none. Labs: serum creatinine 0.8 mg/dL. What is the most important counseling point for a patient on enoxaparin that also supports sharps safety?
Explanation: This question assesses integrated counseling on enoxaparin use, including air bubble management and sharps safety. The key patient-specific factor is the patient's inquiry about the prefilled syringe air bubble post-ankle fracture. Choice A is the most important point as engaging the safety mechanism after injection and immediate disposal supports safety without recapping, while retaining the air bubble ensures full dose delivery. Choice B is incorrect because expelling the bubble leads to underdosing, and choice C is suboptimal as deltoid injection is not standard for enoxaparin. Choice D is wrong due to risks from delayed disposal. A pearl is to inject enoxaparin subcutaneously without expelling air for accurate dosing. Use a framework: explain technique, emphasize safety, ensure disposal.
A 63-year-old man (86 kg) presents for diabetes follow-up at a pharmacist-run clinic. Medical history: type 2 diabetes, hypertension. Medications: metformin 1000 mg twice daily, semaglutide 0.5 mg weekly, losartan 100 mg daily. Labs: HbA1c 6.8%, urine albumin-to-creatinine ratio (UACR) 120 mg/g (normal <30), eGFR 68 mL/min/1.73 m2. Blood pressure: 128/78 mmHg. What is the most important follow-up action based on this patient's screening results?
Explanation: This question tests the concept of managing albuminuria in diabetic kidney disease for nephroprotection. The key patient-specific factor is elevated UACR of 120 mg/g despite losartan and controlled HbA1c, indicating need for additional therapy. Choice B is the best action because recommending SGLT2 inhibitor addition (if appropriate) provides kidney protection per guidelines. Choice A is incorrect as UACR 120 is abnormal and requires intervention; choice C is wrong because ARBs like losartan reduce albuminuria. Choice D is suboptimal as increasing semaglutide primarily for albuminuria is not first-line. A clinical pearl is that SGLT2 inhibitors slow CKD progression in diabetes. Monitor UACR annually in diabetic patients for early intervention.
A pharmacist-researcher runs an IRB-approved vaccine effectiveness study using pharmacy immunization records. A staff member prints participant lists with names and birthdates and leaves them on a public counter, where other customers can see them. What is the primary ethical concern in this study?
Explanation: The ethical concept being tested is confidentiality in handling research data. The key ethical issue is leaving printed identifiable participant lists in a public area, exposing information to unauthorized viewers and breaching privacy. Choice A is the best identification because it highlights the improper safeguarding that violates GCP standards for data protection. Choice B is incorrect as randomization is not the issue; choice C is suboptimal because placebo arms are not required; choice D is unrelated to confidentiality. The transferable principle is that physical and digital data must be secured to prevent breaches and uphold respect for persons. Under GCP and HIPAA, identifiable information must be stored securely to minimize unauthorized access risks.
A 59-year-old male (weight 85 kg, height 176 cm) with deep vein thrombosis is receiving enoxaparin 80 mg subcutaneously every 12 hours. Past history: chronic kidney disease. Current medications: acetaminophen 650 mg every 6 hours as needed and sertraline 50 mg daily; allergies: none. Labs: serum creatinine 2.6 mg/dL, aspartate aminotransferase 21 U/L, alanine aminotransferase 20 U/L, hemoglobin 12.8 g/dL, platelets 210 x10^3/mm^3; anti-factor Xa level (drawn appropriately) is 1.4 IU/mL (typical treatment peak goal ~0.6–1.0 IU/mL). Therapeutic goal: therapeutic anticoagulation while minimizing bleeding. What is the appropriate dose adjustment given the patient's renal function?
Explanation: This question tests understanding of low molecular weight heparin pharmacokinetics in renal impairment. The key patient-specific factors are significant renal impairment (CrCl likely ~30 mL/min), elevated anti-Xa level above therapeutic range, and risk of accumulation with twice-daily dosing. Option C is correct because enoxaparin undergoes significant renal clearance, and in severe renal impairment (CrCl <30 mL/min), twice-daily dosing leads to drug accumulation; guidelines recommend either reducing to once-daily dosing (1 mg/kg daily) or considering alternative anticoagulants like unfractionated heparin with aPTT monitoring. Option A is incorrect because the anti-Xa level is above goal and continuing current dosing risks bleeding. Option B is dangerously wrong as increasing the dose would worsen accumulation. Option D is inappropriate because stopping anticoagulation abruptly without overlap in acute DVT risks clot extension, and warfarin requires bridging until therapeutic INR is achieved. The clinical pearl is that anti-Xa monitoring is recommended for LMWH in renal impairment, obesity, or pregnancy; peak levels should be drawn 4 hours post-dose, and accumulation manifests as elevated anti-Xa levels requiring dose adjustment or agent change.
A 67-year-old woman (weight 70 kg) with nonvalvular atrial fibrillation and hypertension is starting anticoagulation; her creatinine clearance is 55 mL/min. A randomized, open-label, blinded-endpoint trial compared apixaban 5 mg twice daily vs warfarin (international normalized ratio goal 2–3) for stroke/systemic embolism prevention; annual stroke/systemic embolism rates were 1.27% vs 1.60% (hazard ratio 0.79, 95% CI 0.66–0.95; p=0.01) and major bleeding was 2.13% vs 3.09% (hazard ratio 0.69, 95% CI 0.60–0.80; p<0.001). What is the key takeaway from the study for this patient's case?
Explanation: This question evaluates the interpretation of hazard ratios and confidence intervals in superiority trials for anticoagulation outcomes. The key study is a randomized, open-label trial with blinded endpoints comparing apixaban to warfarin in nonvalvular atrial fibrillation, showing lower stroke and bleeding risks with apixaban. The correct answer supports apixaban as appropriate because it demonstrated superior efficacy and safety in a population including those with CrCl >25 mL/min, applicable to this patient's CrCl of 55. Choice B is incorrect as the CI 0.66–0.95 does not cross 1.0, indicating significance; choice C errs in stating the trial was not randomized; choice D misstates the applicability, as the trial included a range of renal functions. Common misinterpretations include confusing open-label with non-randomized designs. A clinical pearl is to prioritize randomized controlled trials for causal inferences in treatment decisions. Framework: Verify if CI excludes the null value (1.0 for ratios) to confirm statistical significance before applying to patients.
A 39-year-old woman with low income presents to the pharmacy with a new prescription for levothyroxine 75 mcg by mouth daily. Medical history: hypothyroidism. Current medications: levothyroxine 75 mcg daily, calcium carbonate 500 mg by mouth twice daily as needed for heartburn; no known drug allergies. She has no insurance, lives in a rural area, and cannot afford follow-up thyroid-stimulating hormone testing; a local community clinic offers discounted labs once monthly. Which factor is most critical to consider in this patient's care plan?
Explanation: This question tests health equity by ensuring access to necessary monitoring for thyroid therapy in low-income, rural patients. The key patient-specific social determinant is lack of insurance and rural location, preventing affordable follow-up TSH testing essential for dose adjustment. Her ability to access and afford laboratory monitoring is most critical, as discounted monthly labs at the clinic could facilitate this. Needing brand-name levothyroxine ignores generic efficacy and cost savings, while refrigeration or liver tests are not required for this medication. A clinical pearl is that barriers to monitoring can lead to suboptimal dosing and poor outcomes in endocrine disorders. In pharmacy practice, incorporate a care coordination framework to connect patients to affordable testing resources for equitable management.
A 63-year-old female (weight 66 kg, height 158 cm) with chronic pain presents with excessive sedation and slowed breathing after starting a new medication yesterday. Current medications: oxycodone immediate-release 10 mg by mouth every 6 hours as needed (uses 3–4 doses/day), gabapentin 600 mg by mouth three times daily, and a new prescription for diazepam 5 mg by mouth three times daily for muscle spasm; allergies: none known. Labs: serum creatinine 0.9 mg/dL (0.6–1.3), alanine aminotransferase 22 units/L (7–56). The prescriber did not document counseling or risk mitigation, and no naloxone was offered. What is the most critical error in this scenario?
Explanation: This case demonstrates an interaction oversight error involving the dangerous combination of benzodiazepines with chronic opioid therapy without appropriate risk mitigation. The key patient-specific factor is the patient's chronic opioid use (oxycodone 3-4 times daily) now combined with diazepam, manifesting as respiratory depression (excessive sedation and slowed breathing). Option C correctly identifies this as an interaction oversight requiring immediate intervention, as the prescriber failed to address the additive CNS depression risk or implement safety measures like naloxone co-prescribing. Option A is incorrect because gabapentin and oxycodone don't have a significant pharmacokinetic interaction; the issue is the new benzodiazepine addition. Option B is wrong as taking diazepam with food for nausea is not the critical safety issue here. Option D is dangerously incorrect, advocating for increased opioid use and delayed reporting, which could result in fatal overdose. The framework for managing opioid-benzodiazepine combinations includes: (1) identifying all patients on chronic opioids before adding benzodiazepines, (2) implementing dose reductions when combination is necessary, (3) co-prescribing naloxone, (4) enhanced monitoring for respiratory depression, and (5) documenting risk-benefit discussions and safety measures.
In a busy retail pharmacy, a technician accidentally selects hydralazine 25 mg instead of hydroxyzine 25 mg during data entry; the pharmacy system’s tall-man lettering and indication prompts are enabled, but the prompt was dismissed. The pharmacist notices the mismatch when reviewing the e-prescription and the patient’s EHR-linked problem list shows chronic pruritus. The pharmacist must use available informatics tools to prevent the error and document appropriately. How should the pharmacist utilize the EHR to improve medication safety?
Explanation: This question tests EHR-linked problem lists and pharmacy system prompts for preventing dispensing errors. The key challenge is correcting look-alike drug selections like hydralazine versus hydroxyzine using informatics to avoid near-misses. Choice A is the best as it verifies indications, corrects entries, and documents, leveraging technology for safety. Choice B is incorrect by dispensing wrong drugs, risking harm; choice C is suboptimal disabling prompts, increasing errors; choice D violates privacy with social media. An informatics pearl is to enable tall-man lettering and prompts to reduce look-alike errors. Ensuring data privacy in verifications protects patient information during error investigations.
A 63-year-old man (88 kg) with heart failure with reduced ejection fraction (LVEF 30%) reports new breast tenderness and enlargement after starting spironolactone 25 mg PO daily 3 months ago. Current medications: sacubitril/valsartan 49/51 mg PO BID, carvedilol 25 mg PO BID, spironolactone 25 mg PO daily, furosemide 40 mg PO daily. Labs: K 4.7 mEq/L, SCr 1.1 mg/dL, AST/ALT normal; allergies: none. Which source provides the best evidence-based recommendation for managing spironolactone-associated gynecomastia while maintaining mortality benefit in HFrEF?
Explanation: This question tests the utilization of cardiology guidelines as tertiary resources for managing adverse effects in heart failure therapy, focusing on ACC/AHA/HFSA recommendations. The key patient-specific factor is spironolactone-induced gynecomastia in a male patient with HFrEF, requiring an alternative to maintain mineralocorticoid receptor antagonist benefits. ACC/AHA/HFSA heart failure guidelines are the best choice, recommending eplerenone as an alternative with lower gynecomastia risk while preserving mortality reduction. CDC immunization schedule is irrelevant for drug adverse effect management; USP monograph addresses compounding, not clinical alternatives; Sanford Guide focuses on antimicrobials, misapplying to heart failure. A transferable clinical pearl is to reference disease-specific guidelines for adverse effect mitigation, ensuring therapy optimization. Selecting appropriate tertiary resources supports evidence-based switches that balance efficacy and tolerability.
In a hospital ICU, a 68-year-old male (82 kg) with atrial fibrillation is ordered a heparin infusion for VTE prophylaxis/therapeutic anticoagulation; the nurse calls because the MAR shows both heparin 25,000 units/250 mL (100 units/mL) and heparin 25,000 units/500 mL (50 units/mL) stocked on the unit. Current meds: metoprolol tartrate 25 mg PO BID, lisinopril 10 mg PO daily, atorvastatin 40 mg PO nightly. Labs: SCr 1.1 mg/dL, AST/ALT 28/32 U/L, INR 1.1, A1c 6.2%; allergies: none. The risk is a high-alert infusion concentration mix-up leading to a 2-fold dosing error. What is the best practice for handling this high-alert medication?
Explanation: This question tests the concept of standardizing concentrations for high-alert medications to prevent infusion errors. The key risk element is the availability of two heparin concentrations on the unit, which could lead to a 2-fold dosing error in a patient requiring therapeutic anticoagulation for atrial fibrillation. Standardizing to a single concentration and requiring independent double-checks is the best choice because it minimizes selection errors and ensures accurate pump programming through verification. Allowing either concentration with only nurse double-checks is suboptimal as it maintains the risk of mix-up without systemic prevention, while converting to subcutaneous heparin ignores the indication and could compromise efficacy. Relying solely on prescriber orders or dispensing both perpetuates the error potential without safeguards. A key clinical pearl is that for high-alert infusions like heparin, standardization and double-checks are essential to reduce variability and harm. Pharmacists should advocate for protocol-driven approaches in risk management to enhance patient safety across settings.
A meta-analysis pooled 6 trials (n = 4,100; mean age 50 years; 64% female) comparing an SSRI vs placebo for generalized anxiety disorder. The pooled response odds ratio was 1.40 (95% CI 1.15 to 1.70; p = 0.001). What is the primary conclusion from the meta-analysis?
Explanation: This question evaluates meta-analysis on SSRIs for anxiety. The key parameter is the odds ratio of 1.40 (95% CI 1.15 to 1.70; p=0.001). Choice A is the best because the CI excludes 1.0, indicating significance. Choice B notes inclusion of 1.0 incorrectly; choice C misinterprets as worsening; choice D dismisses significance. Exclusion of 1.0 supports efficacy. Clinically, integrate with side effects for treatment decisions.
A 31-year-old female (60 kg) presents with flushing, sweating, lacrimation, wheezing, and muscle fasciculations after using an insecticide in a poorly ventilated apartment; she is drooling and has pinpoint pupils. Current medications: albuterol inhaler 2 puffs every 4 hours as needed. Labs: serum creatinine 0.7 mg/dL; aspartate aminotransferase 24 units/L; alanine aminotransferase 20 units/L. Allergies: none. History: asthma; exposure was 30 minutes ago. Which antidote is most appropriate for this exposure?
Explanation: This question tests the management of organophosphate poisoning, emphasizing anticholinergic and reactivator therapy. The key patient-specific factor is the cholinergic toxidrome (wheezing, pinpoint pupils, fasciculations) post-insecticide exposure. Atropine with pralidoxime is best as atropine dries secretions and counters muscarinic effects, while pralidoxime regenerates acetylcholinesterase. N-acetylcysteine is incorrect without acetaminophen; naloxone is for opioids; deferoxamine is for iron. A pearl is to titrate atropine to resolution of bronchial secretions, not heart rate. Early decontamination and airway protection are critical in severe cases to prevent aspiration.
A 34-year-old male (86 kg) calls the pharmacy 30 minutes after taking his first dose of amoxicillin/clavulanate 875/125 mg by mouth twice daily for sinusitis. He reports new generalized hives, lip swelling, and tightness in his throat. Current medications: none. Allergies: seasonal allergies only. Medical history: none. No labs available. What is the most important step in reporting this adverse drug reaction?
Explanation: This question tests recognition and management of anaphylaxis as a severe adverse drug reaction. The patient exhibits classic signs of anaphylaxis (generalized hives, lip swelling, throat tightness) within 30 minutes of first amoxicillin/clavulanate dose, indicating IgE-mediated hypersensitivity. Option A is correct because anaphylaxis is a medical emergency requiring immediate 911 activation, followed by proper documentation and MedWatch reporting once the patient is stabilized. Option B is dangerous as it delays emergency treatment to complete paperwork first. Option C is incorrect because VAERS is specifically for vaccine adverse events, not antibiotics. Option D fails to capture critical details needed for adverse event reporting and patient safety. The clinical pearl is that anaphylaxis requires immediate emergency response first, then comprehensive documentation including timing, symptoms, and interventions, followed by FDA MedWatch reporting for serious adverse events. Pharmacists should document beta-lactam allergies prominently in all systems to prevent future exposures.
In an acute care unit, a nurse reports that the automated dispensing cabinet (ADC) dispensed hydromorphone 2 mg/mL vials when morphine 2 mg/mL vials were selected for restocking. The pharmacy informatics dashboard shows the ADC bin for morphine was recently reassigned after a formulary change, and the hospital requires controlled substance discrepancies to be investigated and documented per policy. Which informatics tool is most appropriate for resolving this medication error?
Explanation: This question tests the use of automated dispensing cabinet (ADC) informatics tools to investigate and resolve medication errors involving controlled substances. The operational challenge is tracing the source of a potentially serious medication error while maintaining regulatory compliance. Option A is the BEST approach as it utilizes ADC transaction logs and audit trails to identify the error source, ensures patient safety through quarantine, and maintains required documentation for controlled substances. Option B abandons objective data in favor of unreliable verbal accounts. Option C dangerously disables safety features that prevent medication errors. Option D creates unacceptable delays and bypasses required documentation for controlled substances. The informatics pearl is that ADC systems maintain detailed transaction logs and user audit trails that are essential for investigating discrepancies, especially with controlled substances, enabling root cause analysis and prevention of future errors.
A 67-year-old male (82 kg) is hospitalized for community-acquired pneumonia and was started empirically on piperacillin/tazobactam 3.375 g IV every 6 hours plus vancomycin 1.25 g IV every 12 hours 48 hours ago. Current medications also include lisinopril 10 mg PO daily and acetaminophen 650 mg PO every 6 hours as needed. Labs: SCr 1.0 mg/dL; AST/ALT 22/19 units/L; WBC 9.8 x10^3/mcL; procalcitonin decreased from 1.8 to 0.4 ng/mL. Sputum culture grows Streptococcus pneumoniae susceptible to penicillin and ceftriaxone; MRSA nasal PCR is negative; blood cultures show no growth. Allergy: rash to sulfonamides. Which intervention is most appropriate for this patient's antimicrobial therapy?
Explanation: This question tests the principle of antimicrobial de-escalation in empirical therapy for community-acquired pneumonia once culture results guide targeted treatment. The key patient-specific factor is the sputum culture revealing Streptococcus pneumoniae susceptible to penicillin and ceftriaxone, combined with negative MRSA nasal PCR and improving procalcitonin. De-escalating to ceftriaxone 1 g IV every 24 hours is the best choice as it provides effective, narrow-spectrum coverage against the identified pathogen while minimizing unnecessary broad-spectrum antibiotic exposure. Continuing piperacillin/tazobactam plus vancomycin is suboptimal as it promotes resistance without added benefit given the susceptibility profile, and switching to trimethoprim/sulfamethoxazole is inappropriate due to the sulfa allergy and lack of first-line indication for pneumococcal pneumonia. Adding azithromycin is unnecessary as there is no evidence of atypical pathogens, and the regimen already covers typical bacteria adequately. A key stewardship pearl is to de-escalate antibiotics based on culture results and clinical improvement to reduce selective pressure for resistance. Always reassess the need for MRSA coverage using tools like nasal PCR to guide vancomycin discontinuation.
A 66-year-old man (weight 85 kg) is admitted with severe pain from metastatic prostate cancer; treatment goal is continuous analgesia with minimal peaks and troughs. Current medications: morphine immediate-release 15 mg orally every 4 hours as needed (insufficient), ondansetron 4 mg orally every 8 hours as needed. He has difficulty swallowing pills due to mucositis. Labs: serum creatinine 1.0 mg/dL. Allergies: none. Which administration route is most appropriate for this patient?
Explanation: This question tests alternative routes for opioid analgesia in patients with swallowing difficulties. Key patient-specific factors include metastatic cancer pain, mucositis, and insufficient oral morphine. Switching to transdermal fentanyl after assessing tolerance with breakthrough opioid is appropriate for continuous relief without oral intake. Crushing extended-release is unsafe; nebulized not indicated; discontinuation inadequate. A transferable clinical pearl is to use transdermal for stable chronic pain in dysphagic patients. For route selection, evaluate pain patterns and tolerance.
A 29-year-old woman (weight 70 kg) with Crohn disease is seen in clinic for maintenance therapy. She has been stable for 8 months on infliximab (Remicade) 5 mg/kg intravenously every 8 weeks; last infusion was 7 weeks ago. Current medications: infliximab as above, azathioprine 100 mg by mouth daily, multivitamin daily. Your health system has added infliximab-dyyb (Inflectra) as the preferred product and the prescriber asks you to switch her at the next infusion. What is the best approach to substituting a biosimilar for this patient's medication?
Explanation: This question tests the principles of switching to a biosimilar for infliximab in Crohn disease, emphasizing safe substitution practices. The key patient-specific factor is stable disease on reference infliximab 5 mg/kg every 8 weeks, with no history of immunogenicity or adverse reactions. Switching to infliximab-dyyb at the same dose and interval with monitoring for loss of response and infusion reactions is the best approach because biosimilars are highly similar with no clinically meaningful differences, and guidelines support switching in stable patients with close follow-up. Increasing the dose to 10 mg/kg is unnecessary and increases risk of adverse effects without evidence of benefit; substituting adalimumab requires prescriber approval and is not equivalent; biosimilars can be used for Crohn disease regardless of interchangeability status. Double the dose for the first month is incorrect as it pertains to a different misconception. A transferable pearl is that biosimilar switches should maintain the same regimen and include patient education on reporting changes in efficacy or safety. Always document the specific product for traceability in case of adverse events.
A 41-year-old man (90 kg) presents with 3 days of watery diarrhea and abdominal cramping after completing clindamycin 300 mg four times daily for 10 days for a dental infection. Medical history: none. Current medications: none besides recent antibiotic. Allergies: none. Labs: white blood cell count 14,500/mm^3 (normal 4,000–11,000), SCr 1.0 mg/dL. Which condition is most consistent with this patient's symptoms?
Explanation: This question tests recognition of antibiotic-associated diarrhea, specifically Clostridioides difficile infection. The key symptoms are watery diarrhea and abdominal cramping following recent clindamycin use, with leukocytosis. Clostridioides difficile infection due to antibiotic-associated gut flora disruption is the best choice because broad-spectrum antibiotics like clindamycin allow C. difficile overgrowth, toxin production, and colitis. Acute pancreatitis presents with epigastric pain and elevated lipase, while irritable bowel syndrome lacks post-antibiotic timing and fever, and appendicitis causes right lower quadrant pain with rebound tenderness. Clinically, testing for C. difficile toxins via PCR or EIA is essential in post-antibiotic diarrhea. A framework includes avoiding high-risk antibiotics in susceptible patients and using fidaxomicin or vancomycin for treatment to reduce recurrence.
A 62-year-old man (91 kg) with gout presents for follow-up after starting allopurinol 4 weeks ago. PMH: gout, CKD stage 3b, HTN. Meds: allopurinol 300 mg PO daily, colchicine 0.6 mg PO daily (prophylaxis), losartan 50 mg PO daily. Labs: SCr 2.1 mg/dL (eGFR 32 mL/min/1.73 m2), uric acid 5.8 mg/dL, CBC WNL, LFTs WNL. He reports no flares and mild diarrhea. Which parameter should be closely monitored for effectiveness?
Explanation: Person-centered assessment and treatment planning for gout involve monitoring uric acid to assess urate-lowering therapy effectiveness. The key patient-specific factor is allopurinol initiation in CKD, where uric acid levels guide dose adjustments. Serum uric acid should be closely monitored for effectiveness, targeting <6 mg/dL to prevent flares. INR is for anticoagulation; troponin for cardiac events; amylase for pancreatitis. In gout management, titrate allopurinol based on uric acid and eGFR. Use prophylaxis like colchicine during initiation to minimize flares.
A 34-year-old female is prescribed progesterone vaginal inserts from a retail pharmacy. The product labeling states to store at controlled room temperature 20–25°C (68–77°F) and avoid excessive heat. She plans to travel internationally and asks whether she should pack them with dry ice. Which recommendation ensures optimal stability for this drug?
Explanation: This question tests travel packing for inserts like progesterone. The main factor is avoiding freezing or heat that alters matrix integrity. Option B advises RT without dry ice, matching labeling. Option A promotes freezing, and option C unnecessary cold; option D heat. Misconceptions involve colder better. Use room-temp carriers. Plan for access and stability in travel counseling.
A pharmacy experiences a break-in overnight and multiple bottles of Schedule II opioids are missing. The pharmacist-in-charge is determining next steps. Under DEA requirements, how should the pharmacist respond to this controlled substance loss?
Explanation: This question tests DEA requirements for reporting theft or significant loss of controlled substances. The key guideline mandates prompt notification to local law enforcement and the DEA via Form 106, detailing the incident to combat diversion. Choice B is correct by following reporting protocols, ensuring regulatory compliance and investigation. Choice A is incorrect as delays violate timely reporting rules, and choice C is wrong because DEA handles losses, not MedWatch. Choice D is misguided since unreported adjustments are illegal. For loss prevention, maintain security and inventory controls. In theft cases, steps include securing the site, inventorying losses, notifying authorities, submitting Form 106, and updating records.
A 82-year-old woman (weight 50 kg) with atrial fibrillation has new-onset delirium and cannot swallow safely; treatment goal is continued rate control. Current medications: metoprolol succinate 50 mg orally once daily (extended-release), apixaban 5 mg orally twice daily. Blood pressure is 128/74 mmHg and heart rate is 92 beats/min. Allergies: none. Which administration route is most appropriate for this patient?
Explanation: This question tests administration routes for beta-blockers in patients with swallowing impairment, focusing on crushable formulations. Key patient-specific factors include atrial fibrillation, delirium, elevated heart rate, and feeding tube use. Switching to metoprolol tartrate immediate-release tablets that can be crushed and administered via feeding tube with appropriate dosing is best for continued rate control. Crushing extended-release alters pharmacokinetics; sublingual or discontinuation is inappropriate. A transferable clinical pearl is to use immediate-release forms for enteral tube administration when extended-release cannot be crushed. For route changes, evaluate formulation compatibility and adjust frequency accordingly.
A 52-year-old male (weight 90 kg) with chronic hepatitis C and cirrhosis is being treated for anxiety with lorazepam, but due to excessive sedation the team plans to use a reduced dose. Medical history: cirrhosis (Child-Pugh class C), anxiety. Current medications: spironolactone 100 mg daily, furosemide 40 mg daily, lactulose 20 g three times daily. Labs: AST 110 U/L (normal 10–40), ALT 95 U/L (normal 7–56), total bilirubin 3.2 mg/dL (normal 0.2–1.2), albumin 2.6 g/dL (normal 3.5–5.0). If the usual lorazepam dose is 1 mg by mouth every 8 hours and the plan is to reduce the total daily dose by 50% due to hepatic impairment, determine the appropriate total daily dose for this patient.
Explanation: This question evaluates hepatic dose adjustment for lorazepam in a patient with severe liver disease. The key patient-specific factor is Child-Pugh class C cirrhosis with laboratory evidence of severe hepatic dysfunction, including elevated bilirubin and low albumin. The correct answer is 1.5 mg/day, calculated by taking the usual total daily dose of 3 mg/day (1 mg every 8 hours = 3 mg/day) and reducing it by 50% as specified (3 mg × 0.5 = 1.5 mg/day). Option A (0.5 mg/day) incorrectly reduces the dose by approximately 83%, which is excessive. Option C (3 mg/day) fails to implement any dose reduction despite severe hepatic impairment. Option D (4.5 mg/day) incorrectly increases the dose by 50% rather than reducing it. For benzodiazepines in hepatic impairment, dose reductions of 50% or more are often necessary due to decreased metabolism and increased sensitivity, with lorazepam being preferred over other benzodiazepines due to its simpler metabolic pathway.